Z-Pak Linked to Sudden Heart Attacks
July 5, 2012 By Rudolph F.X. Migliore, P.C.
The antibiotic Zithromax (Z-Pak) has been linked to sudden Heart Attacks. The law firm of Rudolph F.X. Migliore, P.C. is investigating cases of Zithromax Heart Attack. Azithromycin (Zithromax or Z-Pak) is an antibiotic in the macrolide drug class commonly prescribed to those with sinus infection, bronchitis or pneumonia.
An observational study was published on May 17, 2012 in the New England Journal of Medicine observing Medicaid patients on azithromycin for a 5 day course. The U.S. Food and Drug Administration made an announcement reminding clinicians that QT prolongation can trigger a potentially fatal heart rhythm called torsades de pointe, which has been linked to azithromycin as well as other drugs in the macrolide class.
Macrolides have been under FDA radar since 2011. In March 2012, revisions were made to the drug’s warnings and precautions of the extended release tabs and oral suspension to mention reports of QT prolongation and risk for torsades.
The FDA reminds clinicians to avoid prescribing the antibiotic to those with known prolongation of the QT interval, patients with low potassium, or those currently on medications known to cause QT prolongation. The law firm of Rudolph F.X. Migliore, P.C. is investigating cases of those who have been on Zithromax (Z-Pak) and have suffered a sudden or fatal heart attack.
AUTHOR: Rudolph F.X. Migliore, P.C.
Copyright Rudolph F.X. Migliore, P.C.
More information about Rudolph F.X. Migliore, P.C.
Disclaimer: While every effort has been made to ensure the accuracy of this publication, it is not intended to provide legal advice as individual situations will differ and should be discussed with an expert and/or lawyer. For specific technical or legal advice on the information provided and related topics, please contact the author.
Macrolides have been under FDA radar since 2011. In March 2012, revisions were made to the drug’s warnings and precautions of the extended release tabs and oral suspension to mention reports of QT prolongation and risk for torsades.
The FDA reminds clinicians to avoid prescribing the antibiotic to those with known prolongation of the QT interval, patients with low potassium, or those currently on medications known to cause QT prolongation. The law firm of Rudolph F.X. Migliore, P.C. is investigating cases of those who have been on Zithromax (Z-Pak) and have suffered a sudden or fatal heart attack.
AUTHOR: Rudolph F.X. Migliore, P.C.
Copyright Rudolph F.X. Migliore, P.C.
More information about Rudolph F.X. Migliore, P.C.
View all articles published by Rudolph F.X. Migliore, P.C.
Disclaimer: While every effort has been made to ensure the accuracy of this publication, it is not intended to provide legal advice as individual situations will differ and should be discussed with an expert and/or lawyer. For specific technical or legal advice on the information provided and related topics, please contact the author.
